IGF-1 LR3 vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Substance P |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |